<div id="readability-page-1"><p>Taysha Gene Therapies, Inc. ((TSHA)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Taysha Gene Therapies’ latest earnings call struck an optimistic tone, underscoring strong clinical momentum and regulatory engagement for its Rett syndrome program TSHA-102. Management highlighted compelling efficacy data, supportive FDA dialogue, and a cash runway into 2028, while acknowledging sharply higher spending and uncertainty around the exact timing and requirements for potential approval.</p> <h2>Regulatory Progress and FDA Alignment</h2> <p>Taysha detailed a productive Breakthrough Therapy Type B meeting in which the FDA reaffirmed alignment on a potential BLA pathway for TSHA-102, including the option of using a 6‑month interim analysis. A separate Type C meeting saw the agency endorse the company’s process performance qualification strategy, and the BLA‑enabling PPQ campaign using the commercial process began in April with completion targeted by the fourth quarter of 2026.</p> <h2>Clinical Efficacy Signals and Safety Profile</h2> <p>The company reported continued dosing progress in the REVEAL pivotal and ASPIRE trials, with completion of dosing still expected in the second quarter of 2026. As of the May 2026 cutoff, both high and low doses were generally well tolerated with no treatment‑related serious adverse events or dose‑limiting toxicities, and Part A showed an 83% response rate at six months and 100% at nine months among high‑dose patients.</p> <h2>Developmental Gains and Functional Improvements</h2> <p>Beyond headline response rates, TSHA-102 demonstrated broad clinical benefit in Part A, with 22 developmental milestones achieved across 10 patients. The company also cited 165 additional functional skills gained, averaging roughly 19 per patient, and plans to deliver longer‑term follow‑up data of at least 12 months for all 12 Part A participants later this quarter to reinforce durability.</p> <h2>Preclinical Validation of Delivery Route and Construct</h2> <p>Management emphasized newly published nonhuman primate data showing that lumbar intrathecal and intra‑cisterna magna administration produced comparable and widespread AAV9 distribution in the brain and spinal cord. Additional preclinical work presented in 2026 showed self‑complementary AAV9 delivering about 30‑fold higher neuronal transduction, while the mini MECP2 construct used in TSHA-102 proved functionally comparable to full‑length MECP2.</p> <h2>Commercial Readiness and Market Demand</h2> <p>To prepare for potential launch, Taysha has expanded its commercial leadership team with veterans of prior gene therapy introductions and payer engagement. Market research suggests strong clinician and caregiver preference for minimally invasive intrathecal delivery, with robust interest across age ranges, and the company plans to outline more detailed commercial strategies in the second half of 2026.</p> <h2>Solid Cash Position and Runway</h2> <p>From a balance sheet perspective, Taysha ended March 31, 2026 with $276.6 million in cash and cash equivalents. Management believes this capital is sufficient to fund planned operating expenses, including clinical development, PPQ execution and early commercial build‑out, into 2028, providing a multi‑year runway to navigate regulatory and launch preparations.</p> <h2>Substantial Increase in R&amp;D Spend</h2> <p>Research and development expenses surged to $33.8 million in the first quarter of 2026 from $15.6 million a year earlier, a roughly 117% year‑over‑year increase. The spike reflects accelerated investment in BLA‑enabling PPQ manufacturing, higher clinical costs tied to the REVEAL Part A and B and ASPIRE trials, and expanded R&amp;D headcount including stock‑based compensation.</p> <h2>Higher General &amp; Administrative Costs</h2> <p>General and administrative expenses also climbed, reaching $9.7 million in the quarter versus $8.2 million in the prior‑year period. The increase was driven mainly by higher compensation, including equity‑based pay, and consulting and professional fees associated with commercial launch readiness as the company builds infrastructure around a potential TSHA-102 rollout.</p> <h2>Widening Net Loss</h2> <p>These heavier investments translated into a much larger bottom‑line loss, with first‑quarter 2026 net loss nearly doubling to $42.4 million, or $0.12 per share, from $21.5 million, or $0.08 per share, a year ago. Management framed this as a deliberate ramp in development and preparedness spending to support pivotal trials, PPQ work and early commercial planning ahead of a possible BLA submission.</p> <h2>Approval Timing and Data Uncertainty</h2> <p>Despite encouraging FDA interactions, the timeline for approval remains fluid because the agency has not committed to accepting a six‑month interim data package for full approval. Regulators emphasized that approvability will depend on the totality of evidence and could require 12‑month outcomes or a rolling review structure, leaving investors to weigh potential delays against the strength of the emerging dataset.</p> <h2>Manufacturing and Supply-Chain Considerations</h2> <p>On the operations front, Taysha highlighted that PPQ activities are underway and must be completed by late 2026 to underpin the planned submission scenarios for TSHA-102. The company’s primary manufacturing partner is Catalent’s FDA‑inspected Baltimore facility, but management acknowledged that redundancy strategies for downstream commercial supply are still being evaluated, leaving some exposure to potential disruptions.</p> <h2>Forward-Looking Guidance and Milestones</h2> <p>Looking ahead, Taysha reiterated that dosing in the REVEAL pivotal Part B, which plans to enroll about 15 patients, and in ASPIRE remains on track for completion in the second quarter of 2026. The company expects to report at least 12‑month follow‑up for all 12 Part A patients later this quarter, aims to finish PPQ execution by the fourth quarter of 2026 to support a BLA submission, and will share further commercial planning updates in the back half of 2026.</p> <p>Taysha’s earnings call painted a picture of a company leaning hard into its lead gene therapy opportunity, accepting steeper losses in exchange for rapid clinical, regulatory and manufacturing progress. With impressive early efficacy, supportive preclinical data and a healthy cash buffer, the main questions for investors now center on regulatory requirements, PPQ execution and how quickly TSHA-102 can translate from promising trials to a commercial reality.</p></div>

TSHA

<p>Taysha Gene Therapies, Inc. (TSHA) held its Q1 earnings call, highlighting strong clinical momentum for its Rett syndrome program TSHA-102. The company reported positive FDA interactions regarding a potential BLA pathway and ongoing clinical trials. Taysha's cash position stands at $276.6 million, sufficient to fund operations into 2028. However, R&D expenses surged to $33.8 million, leading to a net loss of $42.4 million. Approval timelines remain uncertain, with the FDA's requirements for data still fluid, impacting investor sentiment.</p>

Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA